Healthcare 18 August 2025 - 18 February 2026

UnitedHealth stock slips as Medicare Advantage plan disruptions hit headlines — what to watch before April 6
···

UnitedHealth stock slips as Medicare Advantage plan disruptions hit headlines — what to watch before April 6

UnitedHealth shares slipped 0.1% to $288.83 Wednesday as a new study reported nearly 3 million Medicare Advantage enrollees had to switch plans in 2026 due to insurer exits. UnitedHealthcare accounted for 14% of disruptions, with higher rates in rural areas. CMS set a Feb. 25 deadline for comments on 2027 Medicare Advantage proposals, with a rate announcement due by April 6.
February 18, 2026
Eli Lilly stock slips even after Zepbound-Taltz psoriasis data; investors eye what’s next for LLY
···

Eli Lilly stock slips even after Zepbound-Taltz psoriasis data; investors eye what’s next for LLY

Eli Lilly shares dropped 1.8% to $1,017.86 by late morning Wednesday, underperforming the S&P 500. The company reported late-stage trial data showing its Zepbound-Taltz combination improved skin and weight outcomes in psoriasis patients versus Taltz alone. Investors remain cautious about Lilly’s ability to expand use-cases and defend pricing as competition increases.
February 18, 2026
UnitedHealth stock price slips as CEO investment report renews scrutiny
···

UnitedHealth stock price slips as CEO investment report renews scrutiny

UnitedHealth shares fell 0.8% to $290.89 by late morning after a Wall Street Journal report flagged CEO Stephen Hemsley’s private investments in healthcare startups, raising conflict-of-interest questions. The company said Hemsley’s holdings are in a trust managed by independent trustees. Medicare Advantage rate deadlines and slower enrollment growth also weighed on the stock. Managed-care peers mostly traded higher.
February 17, 2026
UnitedHealth stock pauses for a holiday — new Medicare Advantage numbers set up the next move
···

UnitedHealth stock pauses for a holiday — new Medicare Advantage numbers set up the next move

UnitedHealth Group shares climbed 3.1% to $293.19 Friday, with 10.3 million shares traded before U.S. markets closed for Presidents Day. New federal data show Medicare Advantage enrollment growth slowing to 3% year over year, raising questions about managed-care margins. Peers like Humana have flagged profit pressure after lower government quality scores. Investors await CMS updates on 2027 rates, due by April 6.
February 16, 2026
Healthcare stocks head into Presidents Day break on Moderna rebound, Wegovy copycat fight
···

Healthcare stocks head into Presidents Day break on Moderna rebound, Wegovy copycat fight

The S&P 500 Health Care index rose 1.01% to 1,835.92 on Friday, with Dexcom up 7.6% and Moderna up 5.3% after earnings. Moderna warned of regulatory uncertainty after the FDA refused to review its flu shot. Disc Medicine shares fell 21% after the FDA declined to approve its rare-disease drug. U.S. markets close Monday for Presidents Day; Medtronic reports Tuesday.
February 14, 2026
UnitedHealth (UNH) stock price today: shares rise as healthcare gets a bid, but Medicare Advantage rates still loom
···

UnitedHealth (UNH) stock price today: shares rise as healthcare gets a bid, but Medicare Advantage rates still loom

UnitedHealth shares rose 1.3% to $288.14 in midday New York trading Friday, with nearly 4 million shares changing hands. Managed-care stocks gained despite warnings on Medicare Advantage plan ratings and uncertainty over 2027 reimbursement rates. Humana, Elevance, Cigna, and CVS Health also traded higher. CMS will announce final 2027 Medicare Advantage payment rates by April 6.
February 13, 2026
AbbVie stock jumps as Botox Medicare lawsuit puts Washington back in focus
···

AbbVie stock jumps as Botox Medicare lawsuit puts Washington back in focus

AbbVie shares rose nearly 3% after the company sued U.S. health agencies to block Medicare price controls for Botox. The lawsuit argues Botox should be exempt from the Inflation Reduction Act’s negotiation program as a plasma-derived product. Investors are watching for early court developments and the Medicare timeline for 2028 prices. The case was assigned to U.S. District Judge Carl Nichols.
February 12, 2026
Amazon stock premarket: AMZN health-care push in focus as Wall Street weighs spending and CPI
···

Amazon stock premarket: AMZN health-care push in focus as Wall Street weighs spending and CPI

Amazon Pharmacy will expand same-day prescription delivery to 4,500 U.S. cities and towns by the end of 2026, adding nearly 2,000 communities, Reuters reported. Amazon shares closed down 1.4% at $204.08 ahead of Thursday trading. The company projected $200 billion in capital expenditures for 2026, up from $131 billion in 2025, mostly for AI infrastructure. Investors remain focused on spending and Friday’s inflation data.
February 12, 2026
Medtronic stock slips as earnings near, even after Needham upgrade flags new launches
···

Medtronic stock slips as earnings near, even after Needham upgrade flags new launches

Medtronic shares slipped 0.9% to $100.53 Wednesday afternoon, trailing gains in the S&P 500 ETF. The drop comes ahead of the company’s Feb. 17 fiscal Q3 results and management update. Needham upgraded the stock to “buy,” citing new product launches and activist involvement. Analyst price targets remain widely spread, with Needham’s at $121 and consensus near $106.
February 11, 2026
Elevance Health stock bounces as House subpoenas revive Obamacare subsidy scrutiny
···

Elevance Health stock bounces as House subpoenas revive Obamacare subsidy scrutiny

Elevance Health shares climbed 1.5% to $330.68 Wednesday after rebounding from an intraday low, as subpoenas from the House Judiciary Committee targeted the company and other insurers over ACA premium subsidies. Trading volume reached 0.67 million shares. Other major managed-care stocks mostly rose. RBC Capital Markets recently downgraded Elevance, citing a softer 2026 outlook and lower margin targets.
February 11, 2026
Abbott stock rises on AFib device data buzz as traders weigh FDA overhang
···

Abbott stock rises on AFib device data buzz as traders weigh FDA overhang

Abbott shares climbed 1.5% to $112.68 Tuesday, outperforming a flat healthcare sector as new atrial fibrillation device data drew investor attention. The company reported 93.9% complete closure at 45 days in its VERITAS study and 84.2% one-year freedom-from-recurrence with its Volt PFA system. Investors remain alert to fallout from Abbott’s recent diabetes sensor recall. Trading volume was near typical levels.
February 10, 2026
Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions
···

Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions

Novartis said AI reduced trial site selection for a 14,000-person Leqvio study to a two-hour meeting. Drugmakers report AI is cutting weeks from clinical trial logistics and regulatory paperwork. AstraZeneca and others still face challenges managing thousands of regulatory documents. Analysts say it may take one to three years before investors see the full impact on drug development timelines.
January 26, 2026
Yamanaka Factors Are Resetting Aging Cells
······

Rewinding the Clock: How Yamanaka Factors Are Resetting Aging Cells

In 2022, 124-week-old mice treated with inducible OSK via AAV9 and a 1-day-on/6-days-off cycle lived about twice as long in remaining lifespan, with a 9–12% median lifespan extension. Earlier studies showed partial reprogramming with OSKM extended lifespan and improved tissue function in mice. Human cell experiments reset aging markers by about 30 years. Safety concerns, including cancer risk, remain unresolved.
August 18, 2025
1 2